AcelRx Pharmaceuticals Inc  

(Public, NASDAQ:ACRX)   Watch this stock  
Find more results for ACRX
9.52
-0.08 (-0.83%)
Real-time:   10:46AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 9.40 - 9.65
52 week 2.27 - 10.59
Open 9.65
Vol / Avg. 49,855.00/587,299.00
Mkt cap 354.50M
P/E     -
Div/yield     -
EPS -1.48
Shares 37.24M
Beta     -
Inst. own 79%
Jun 4, 2013
AcelRx Pharmaceuticals, Inc. at Jefferies Global Healthcare Conference - Webcast
May 22, 2013
AcelRx Pharmaceuticals, Inc. at UBS Global Healthcare Conference - Webcast
May 21, 2013
Orthopedic Phase 3 Results - Webcast
May 8, 2013
Q1 2013 AcelRx Pharmaceuticals, Inc. Earnings Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin -1357.66% -1393.61%
Operating margin -1124.36% -1241.14%
EBITD margin - -1215.87%
Return on average assets -87.13% -63.33%
Return on average equity -183.57% -130.03%
Employees 25 -
Carbon Disclosure Rating - -

Address

351 Galveston Drive
REDWOOD CITY, CA 94063
United States - Map
+1-650-2163500 (Phone)
+1-650-2166500 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

AcelRx Pharmaceuticals, Inc. is a United States-based Pharmaceutical Company, which develops and commercializes therapies for the treatment of pain. The Company's products include ARX-01 Sufentanil NanoTab PCA System, to solve the problems associated with post-operative intravenous patient-controlled analgesia (IV PCA); ARX-02 Sufentanil NanoTab BTP Management System is a treatment option for cancer patients who suffer from breakthrough pain (BTP). ARX-03 Sufentanil/Triazolam NanoTab, provides non-invasive mild sedation, anxiety reduction and pain relief; and ARX-04 Sufentanil Acute Pain NanoTab, is a sublingual sufentanil product candidate designed to provide a non-invasive, fast-onset treatment of patients with moderate-to-severe acute pain, both on the battlefield and in civilian settings of trauma or injury.

Officers and directors

Adrian Adams Independent Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Richard A. King M.B.A. President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
James H. Welch Chief Financial Officer
Age: 55
Bio & Compensation  - Reuters
Pamela P Palmer M.D.,Ph.D. Chief Medical Officer, Director
Age: 50
Bio & Compensation  - Reuters
Badri N Dasu Chief Engineering Officer
Age: 49
Bio & Compensation  - Reuters
Lawrence G. Hamel Chief Development Officer
Age: 61
Bio & Compensation  - Reuters
Mark G. Edwards Independent Director
Age: 55
Bio & Compensation  - Reuters
Stephen J Hoffman PhD, MD Independent Director
Age: 58
Bio & Compensation  - Reuters
Guy P. Nohra MBA Independent Director
Age: 52
Bio & Compensation  - Reuters
Howard B Rosen Independent Director
Age: 54
Bio & Compensation  - Reuters